Warfarin, a juggler's demise.
In: Blood, Jg. 131 (2018-06-21), Heft 25, S. 2742-2743
academicJournal
Zugriff:
Warfarin, an anticoagulant therapy used bymillions worldwide, inhibits vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby dampening the carboxylation and the procoagulant potential of vitamin K-dependent coagulation factors. However, the detailed molecular mechanism by which warfarin inhibits VKORC1 remains the subject of debate.1,2 In this issue of Blood, Rishavy et al3 puts this issue to rest by demonstrating that warfarin inhibits VKORC1 via a mechanism termed "the uncoupling of VKORC1." The uncoupling of VKORC1 is significant because it highlights a potential cooperation of VKORC1 with a secondwarfarin-resistant vitaminK quinone reductase, thereby explaining howconsiderable carboxylation can proceed despite the presence of warfarin, and this may have direct implications for warfarin dosing in patients. [ABSTRACT FROM AUTHOR]
Titel: |
Warfarin, a juggler's demise.
|
---|---|
Autor/in / Beteiligte Person: | Mosnier, Laurent O. |
Zeitschrift: | Blood, Jg. 131 (2018-06-21), Heft 25, S. 2742-2743 |
Veröffentlichung: | 2018 |
Medientyp: | academicJournal |
ISSN: | 0006-4971 (print) |
DOI: | 10.1182/blood-2018-05-843151 |
Schlagwort: |
|
Sonstiges: |
|